8 research outputs found
Randomized Trial of 2 Hormonal and 2 Prostaglandin-inhibiting Agents in Women with a Complaint of Menorrhagia
Danazol in the Treatment of Menorrhagia: The Effect of a 1 Month Induction Dose (200 mg) and 2 Month's Maintenance Therapy (200 mg, 100 mg, 50 mg or placebo)
Efficacy and Safety of Oral Tranexamic Acid in Women with Heavy Menstrual Bleeding and Fibroids
A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss
Tranexamic acid therapy for heavy menstrual bleeding
Introduction: Heavy menstrual bleeding (HMB, also known as menorrhagia) is an important health problem that interferes with women's quality of life. It is one of the most common reasons why women are seen by their family doctors in primary care and is a condition frequently treated by surgery.
<p/>Areas covered: This review covers the pharmacology of tranexamic acid in brief and concentrates on its use in the treatment of HMB. Papers published in the English language between January 1985 and November 2010 were reviewed using Medline, Embase, Cinahl and the Cochrane Database of Systematic Reviews. Search terms were ‘heavy menstrual bleeding’, ‘tranexamic acid’ and ‘menorrhagia’.
<p/>Expert opinion: Tranexamic acid, a competitive inhibitor of plasminogen activation, has been used to treat HMB for well over four decades. Although several treatment options are available for HMB, tranexamic acid is particularly useful in women who either desire immediate pregnancy or for whom hormonal treatment is inappropriate. Tranexamic acid is a well-tolerated, cost-effective drug that reduces menstrual blood loss in the range of 34 – 59%. It improves the health-related quality of life in women in HMB